MAP2K7 and melanoma: Overall, PDXCs recapitulate the resistance to BRAF and MEK inhibitor therapy observed in the patient, and PDXCs from treatment-naive BRAF-mutant melanoma patients showed a marked response to BRAF and MEK inhibitor therapy.